A month after acquiring obesity biotech Metsera, Pfizer's expanding in the weight loss drug market after signing a licensing ...

Leaders at the U.S. Food and Drug Administration have pressed internally for reviewers to speed up their evaluation of Eli ...

Leaders at the U.S. Food and Drug Administration have pressed internally for reviewers to speed up their evaluation of Eli Lilly's experimental weight‑loss pill, after the company pushed for a faster ...

A recently approved antibody drug from Regeneron Pharmaceuticals eradicates residual traces of multiple myeloma after initial ...

Big American drugmakers are hunting for novel weight loss drugs in the labs of China’s biotech industry, while U.S.

Regeneron is finding ways to deal with the increased competition to one of its key growth drivers. The company is also ...

Biocon Ltd. has launched its drug-device combination for diabetes and obesity, Diavorin and Vobexoryn respectively, in the Netherlands via Pharmamedic BV.

The Commissioner’s National Priority Voucher program was launched in June to shorten review times for companies that align ...

Johnson & Johnson, which did not apply for the national priority voucher, was granted the ticket based on results from a ...

An Institute for Value-Based Medicine ® event held in New Haven, Connecticut, on October 30, 2025, brought together a diverse ...

Get the latest stock market and healthcare sector updates, top gainers and losers, and key regulatory news impacting investments.

Eli Lilly's innovation and pipeline diversification support long-term growth, despite patent risks and competition. Read more ...